Cargando…
Real-World Data on Newly Diagnosed BRCA-Mutated High-Grade Epithelial Ovarian Cancers: The French National Multicenter ESME Database
SIMPLE SUMMARY: BRCA-mutated high-grade epithelial ovarian cancers represent a specific subset of gynecological malignancies. Real-world comprehensive data have been elusive to date. As such, we conducted a comprehensive description of clinicopathological and therapeutical characteristics via the Ep...
Autores principales: | Bini, Marta, Quesada, Stanislas, Meeus, Pierre, Rodrigues, Manuel, Leblanc, Eric, Floquet, Anne, Pautier, Patricia, Marchal, Frédéric, Provansal, Magali, Campion, Loïc, Causeret, Sylvain, Gourgou, Sophie, Ray-Coquard, Isabelle, Classe, Jean-Marc, Pomel, Christophe, De La Motte Rouge, Thibault, Barranger, Emmanuel, Savoye, Aude Marie, Guillemet, Cécile, Gladieff, Laurence, Demarchi, Martin, Rouzier, Roman, Courtinard, C, Romeo, Clémence, Joly, Florence |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406396/ https://www.ncbi.nlm.nih.gov/pubmed/36011033 http://dx.doi.org/10.3390/cancers14164040 |
Ejemplares similares
-
Management and outcome of male metastatic breast cancer in the national multicenter observational research program Epidemiological Strategy and Medical Economics (ESME)
por: Sirieix, Junien, et al.
Publicado: (2020) -
Practical ESM analysis
por: Robertson, Sue
Publicado: (2019) -
Treatment and outcomes of older versus younger women with HER2-positive metastatic breast cancer in the real-world national ESME database
por: Annonay, Mylène, et al.
Publicado: (2021) -
How and when to refer patients for oncogenetic counseling in the era
of PARP inhibitors
por: Neviere, Zoé, et al.
Publicado: (2020) -
Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database
por: Courtinard, Coralie, et al.
Publicado: (2023)